ESCC and GC/GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr)
TEVIMBRA is a prescription medicine used to treat adults with: cancer of the tube that connects your throat to your stomach (esophageal cancer). TEVIMBRA may be used in combination with …
1.2 Gastric Cancer TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative …
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric ...
Dec 27, 2024 · “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to …
FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable ...
Dec 27, 2024 · Key Takeaways Tislelizumab-jsgr (Tevimbra) approved for first-line treatment of HER2-negative gastric or GEJ adenocarcinoma with PD-L1 expression. Phase 3 RATIONALE-305 trial …
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2 ...
Jan 2, 2025 · Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction ...
TEVIMBRA Received FDA Approval as First-Line Therapy for ...
Dec 28, 2024 · The prognosis for patients with gastric or GEJ cancer depends on the stage at diagnosis, treatment response, and overall health. Immunotherapies, such as TEVIMBRA (tislelizumab), offer a …
Tevimbra by BeiGene approved in US for initial gastric cancer ...
Jan 9, 2025 · BeiGene has received approval from the US Food and Drug Administration (FDA) for its PD-1 inhibitor, Tevimbra (tislelizumab), to be used in combination with chemotherapy for the …
Tislelizumab Approval Gastric Cancer Treatment
Jan 15, 2025 · The FDA has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic …
FDA Approves Tislelizumab-jsgr (Tevimbra) Combo for Gastric ...
Dec 30, 2024 · The U.S. Food and Drug Administration approved tislelizumab-jsgr (Tevimbra) in combination with chemotherapy as a first-line treatment for adults with unresectable or metastatic …
TEVIMBRA Approved in US for 1L Treatment of Gastric and GEJ ...
Dec 31, 2024 · “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to …